$2.94
3.61% today
Nasdaq, Apr 03, 06:50 pm CET
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

ImmunityBio Inc Stock price

$3.05
+0.20 7.02% 1M
-0.52 14.57% 6M
+0.49 19.14% YTD
-2.22 42.13% 1Y
-3.09 50.33% 3Y
+0.40 15.09% 5Y
-31.59 91.20% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.09 3.04%
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

Key metrics

Market capitalization $2.60b
Enterprise Value $3.24b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 219.93
P/S ratio (TTM) P/S ratio 176.47
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 2,270.58%
Revenue (TTM) Revenue $14.75m
EBIT (operating result TTM) EBIT $-344.18m
Free Cash Flow (TTM) Free Cash Flow $-398.12m
Cash position $149.81m
EPS (TTM) EPS $-0.63
P/E forward negative
P/S forward 24.72
EV/Sales forward 30.80
Short interest 18.71%
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a ImmunityBio Inc forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a ImmunityBio Inc forecast:

Buy
80%
Hold
20%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
15 15
2,279% 2,279%
100%
- Direct Costs 18 18
19% 19%
119%
-2.81 -2.81
87% 87%
-19%
- Selling and Administrative Expenses 136 136
54% 54%
920%
- Research and Development Expense 188 188
18% 18%
1,276%
-327 -327
4% 4%
-2,214%
- Depreciation and Amortization 18 18
19% 19%
119%
EBIT (Operating Income) EBIT -344 -344
5% 5%
-2,333%
Net Profit -414 -414
29% 29%
-2,804%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Neutral
Business Wire
8 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations and recent R&D advancements. Key timelines for catalysts of product candidates will b...
Neutral
Business Wire
21 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the first providers to participate in ImmunityBio's Expanded Access Program (EAP) for recombinant Bacillus Calmette-Guérin (rBCG) to address the curre...
Negative
Seeking Alpha
27 days ago
ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expand...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 680
Founded 2014
Website www.immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today